Navigation Links
Cross-country collaboration leads to new leukemia model
Date:7/31/2013

Eight years ago, two former Stanford University postdoctoral fellows, one of them still in California and the other at the Harvard Stem Cell Institute (HSCI) in Cambridge, began exchanging theories about why patients with leukemia stop producing healthy blood cells. What was it, they asked, that caused bone marrow to stop producing normal blood-producing cells?

And after almost a decade of bicoastal collaboration, Emmanuelle Passegu, now a professor in the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at the University of California, San Francisco, and Amy Wagers, a professor in Harvard's Department of Stem Cell and Regenerative Biology, have the answer.

They have found that cancer stem cells actively remodel the environment of the bone marrow, where blood cells are formed, so that it is hospitable only to diseased cells. This finding could influence the effectiveness of bone marrow transplants, currently the only cure for late-stage leukemia, but with a 25 percent success rate due to repopulation of residual cancer cells.

Their results, which were recently published online in Cell Stem Cell, show that leukemia cells cannot replicate in the bone marrow niche as well as healthy blood-forming stem cells can, so the cancer cells gain the advantage by triggering bone marrow-maintenance cells to deposit collagen and inflammatory proteins, leading to fibrosis or scarring of the bone marrow cavity.

"They remodel the microenvironment so that it is basically callous, kicking the normal stem cells out of the bone marrow and encouraging the production of even more leukemic cells," Passegu said. This model is a shift from the widely held theory that cancer cells simply crowd out the healthy cells.

Passegu and Wagers stayed in touch, despite the distance between their laboratories, via annual, two-day, "off-the-record" symposiums of junior investigators at the Harvard Stem Cell Institute and
'/>"/>

Contact: B. D. Colen
bd_colen@harvard.edu
617-495-7821
Harvard University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. La Jolla Institute continues longtime collaboration with Kyowa Hakko Kirin California
2. Ben-Gurion U. and UChicago research collaboration targets water resource innovations
3. NIH to fund collaborations with industry to identify new uses for existing compounds
4. First international collaboration to showcase latest body of evidence of dairy health benefits
5. Missouri Botanical Garden program announces collaboration with LHerboretum
6. Missouri Botanical Garden program annouces collaboration with LHerboretum
7. Collaboration to establish new computational resources for metabolomics
8. Oregon Biodiversity Information Center wins 2013 Natureserve Network Collaboration Award
9. Nottingham-Australia collaboration on environmental conservation of the future
10. Harvards Wyss Institute and Sony DADC announce collaboration on Organs-on-Chips
11. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... out of York University shows a surprisingly effective way ... fungus: moose saliva (yes moose saliva). , Published ... inhibits a grassendophyte mutualism" shows that moose and reindeer ... a fungus called epichlo festucae that produces the toxin ... , "Plants have evolved defense mechanisms to protect themselves, ...
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
(Date:7/24/2014)... fire hazard in the United States, wildland managers often ... and suppressed trees (ladder fuels). These cuttings and ... low fire danger in order to dispose of the ... pollutants, managers often cover all or part of the ... as agricultural plastic, in order to keep water out. ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... years of feathers from natural history museums in the ... track increases in the neurotoxin methylmercury in the black-footed ... forages extensively throughout the Pacific. The ... most likely from human-generated emissions, can be observed and ...
... MARC (Minority Access to Research Careers) Program has announced ... Lakes Bioinformatics Conference (GLBIO) to be held at Ohio ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
... Oxygenation brings dead sea bottoms to life. This ... ecosystems that enable nature itself to deal with eutrophication. ... researchers at the University of Gothenburg have demonstrated that ... effective. A large wind-driven pump is now to be ...
Cached Biology News:Mercury on the rise in endangered Pacific seabirds 2Oxygenation at a depth of 120 meters can save the Baltic Sea 2
(Date:7/23/2014)... have made great strides in saving China,s endangered national ... over 65 giant panda reserves that have been established ... just 1596 pandas remain in the wild. , ... save the panda by improving genetic diversity, avoid inbreeding ... how are these high-profile programs doing so far? , ...
(Date:7/23/2014)... LOS ANGELES , July 23, 2014 /PRNewswire-iReach/ -- ... enhance cognitive performance for the long term. They are ... competitive edge of sustained energy as an alternative to ... launch Think Drinks on Indiegogo on July 29, 2014, ... the 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... Last year, Formedix celebrated ... global provider of data management solutions for clinical trials. ... system for electronic data capture (EDC) and clinical data ... study execution tools added TrialMaster to its Transform for ... of Transform for TrialMaster, is being released this week, ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3
... Calif., Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ... results for 2007 after the market closes on Tuesday, ... at 4:30 p.m. EST,1:30 p.m. PST, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... initiated by end of 2007 -, PRAGUE, Czech ... ) and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... reduction in new or,enlarged gadolinium-enhancing lesions when daclizumab is ... multiple,sclerosis (MS). These data will be presented tomorrow at ...
... LOWELL, Mass., Oct. 11 More than half ... but,are concerned about the current state and national economies, ... today by the Massachusetts,Economic Assessment and Analysis Project (MEAAP) ... Fifty-four percent of those surveyed said their own ...
Cached Biology Technology:CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6Survey Sees Mass. CEOs as Bullish on Own Businesses 2
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
Fetal Calf Serum Replacement (Bistec) serum...
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Biology Products: